The Filing Desk

Precigen vs Zenas BioPharma

Precigen PGEN · Zenas BioPharma ZBIO · Pharmaceuticals

Zenas BioPharma reported revenue of $10 million in fiscal 2025, about the same as Precigen's $10 million in fiscal 2025. Precigen's revenue grew 146.7% in its latest year, and Zenas BioPharma's grew 100.0%. Precigen had an operating margin of -1141.1%, against -3830.6% at Zenas BioPharma. Free cash flow was −$90 million at Precigen and −$172 million at Zenas BioPharma.

Side by side

PrecigenZenas BioPharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$10M$10M
Revenue growth146.7%100.0%
Revenue growth a year, last 5 years−21.2%—
Gross margin——
Operating margin−1,141.1%−3,830.6%
Net margin−2,588.2%−3,777.4%
Free cash flow−$90M−$172M
Free cash flow margin−927.6%−1,723.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count16.9%238.9%
Last close$4.54$28.01
P/E at the last close45.4×—
Insider trades, last 12 months——
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
PrecigenZenas BioPharma
Operating margin
Percent of revenue
PrecigenZenas BioPharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PrecigenZenas BioPharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Precigen and Zenas BioPharma pages.